Showing results (431-440 of 458) with videos related to

Sort By:
Pageof 46
Cell Reports. Medicine|September 29, 2023
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcomaMeijie Tian, Jun S Wei, Nityashree Shivaprasad, et al.
Cancer Research|February 19, 2021
GAS7 Deficiency Promotes Metastasis in MYCN-Driven NeuroblastomaZhiwei Dong, Kok Siong Yeo, Gonzalo Lopez, et al.
Nature|December 3, 2010
Integrative genomics identifies LMO1 as a neuroblastoma oncogeneKai Wang, Sharon J Diskin, Haitao Zhang, et al.
Journal of the National Cancer Institute|March 8, 2018
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma PatientsPauline Depuydt, Valentina Boeva, Toby D Hocking, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Atomically accurate de novo design of antibodies with RFdiffusionNathaniel R Bennett, Joseph L Watson, Robert J Ragotte, et al.
Nature|March 1, 2018
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumoursXiaotu Ma, Yu Liu, Yanling Liu, et al.
Cancers|April 30, 2021
A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood NeuroblastomaLaura D Gamble, Stefania Purgato, Michelle J Henderson, et al.
Nature|November 5, 2025
Atomically accurate de novo design of antibodies with RFdiffusionNathaniel R Bennett, Joseph L Watson, Robert J Ragotte, et al.
Nature Medicine|April 3, 2023
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C Goldsmith, Julie R Park, Kimberly Kayser, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaLucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
Pageof 46